Verona Pharma plc is a biopharmaceutical company focused on developing therapies for chronic respiratory diseases. The company concentrates on conditions with high unmet medical need, such as chronic obstructive pulmonary disease (COPD) and non-cystic fibrosis bronchiectasis, aiming to improve symptom control and reduce exacerbations.
Its lead program is ensifentrine, an inhaled, first-in-class dual phosphodiesterase 3 and 4 (PDE3/PDE4) inhibitor designed to provide both bronchodilator and non-steroidal anti-inflammatory effects in a single molecule. Verona Pharma advances its candidates through clinical development and works with healthcare stakeholders to enable access to new treatments for respiratory patients.